Caristo Diagnostics' CaRi-Heart® Coronary Inflammation Technology Authorized by U.S. FDA

RegulatoryapprovedCaRi-Heart®Positive

AI Analysis

Summary

Caristo Diagnostics received FDA authorization for CaRi-Heart®, a coronary inflammation biomarker technology that identifies cardiovascular risk up to 10 years in advance. The authorization positions CaRi-Heart® as the first and only biomarker of its kind, enabling personalized cardiovascular disease management.

Outcome Details

FDA authorization of CaRi-Heart® Coronary Inflammation Technology as a biomarker to measure coronary inflammation and assess cardiovascular mortality risk

Importance:7/10

Sentiment:

0.85

FDA approvaldiagnostic biomarkercardiovascular riskcoronary inflammationpersonalized medicine

Related Companies

$ONT.L $TRAX

Read the original article

Published by PR Newswire Biotech on July 29, 2026 2:00 PM

Read Original